Lifecore Biomedical (NASDAQ:LFCR – Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.78), FiscalAI reports. The company had revenue of $25.32 million for the quarter, compared to analysts’ expectations of $25.57 million.
Lifecore Biomedical Stock Performance
Shares of LFCR stock traded down $0.06 during mid-day trading on Thursday, hitting $6.38. 370,654 shares of the stock were exchanged, compared to its average volume of 284,398. The stock’s fifty day simple moving average is $5.53 and its two-hundred day simple moving average is $5.51. The stock has a market capitalization of $242.06 million, a price-to-earnings ratio of -5.97 and a beta of 0.99. Lifecore Biomedical has a 12-month low of $3.63 and a 12-month high of $8.98.
Wall Street Analyst Weigh In
LFCR has been the topic of a number of analyst reports. Zacks Research raised Lifecore Biomedical from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. Craig Hallum lowered shares of Lifecore Biomedical from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 28th. Weiss Ratings raised shares of Lifecore Biomedical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 16th. Barrington Research downgraded shares of Lifecore Biomedical from an “outperform” rating to a “hold” rating in a research note on Tuesday, September 29th. Finally, William Blair downgraded shares of Lifecore Biomedical from an “outperform” rating to a “hold” rating in a research note on Monday, September 28th. Four equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Lifecore Biomedical currently has a consensus rating of “Reduce” and a consensus target price of $6.50.
Read Our Latest Stock Report on LFCR
About Lifecore Biomedical
Lifecore Biomedical, Inc is a contract development and manufacturing organization that provides development, formulation, aseptic filling, packaging and other manufacturing services for pharmaceutical and biopharmaceutical companies. The company specializes in complex sterile injectable products and supports customers from development through commercial production.
Lifecore has particular expertise in hyaluronic acid, a naturally occurring substance used in ophthalmic, orthopedic, aesthetic and other medical applications.
See Also
- Five stocks we like better than Lifecore Biomedical
- South Korea’s Chip Exports Are Soaring—So Why Is This ETF Down 20%?
- Uber’s Profit Drop: A Speed Bump or Structural Shift?
- Boeing Has the Orders, the Cash Flow, and Insider Buyers, But What’s Still Missing?
- The Fed Is Split on Rates—Why These 2 Treasury ETFs Could Have an Edge
Receive News & Ratings for Lifecore Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lifecore Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.
